Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of efficacy and safety of twice-daily NovoMix 30 in type 2 diabetes
KCT0000388Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2007
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of biphasic insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoints: Glycemic control efficacy and Safety profile. Started Jul 2007; status: completed.
02
Drugs
biphasic insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0000388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000388.